Melaleuca Allergy: Why the Real Culprit Is Bahiagrass (Stablein 2002)
Melaleuca (paperbark tree, Melaleuca quinquenervia) showed 9.5% SPT positivity in Florida — until Stablein and Lockey (Ann Allergy Asthma Immunol 2002) proved that apparent melaleuca allergy reflects cross-reactivity with windborne bahiagrass, not primary sensitization. Melaleuca is bee-pollinated with pollen too heavy to drive primary IgE disease. SCIT for melaleuca is unfounded; Florida patients positive on melaleuca testing should be evaluated and treated for bahiagrass.
Melaleuca (Paperbark Tree) Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to melaleuca (paperbark tree) — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of melaleuca (paperbark tree) allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of melaleuca (paperbark tree) immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of melaleuca (paperbark tree) extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for melaleuca (paperbark tree) allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing melaleuca (paperbark tree) extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription melaleuca (paperbark tree) immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat melaleuca (paperbark tree) allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Melaleuca (Paperbark Tree)?
The biology, taxonomy, and clinical fingerprint of Melaleuca (Paperbark Tree) — the foundation of how SCIT targets it.
Melaleuca quinquenervia (paperbark tree) — invasive in the Florida Everglades, bee-pollinated. Apparent 9.5% SPT positivity in Florida reflects bahiagrass cross-reactivity, not primary Melaleuca sensitization. SCIT for melaleuca is unfounded.
- Scientific name
- Melaleuca quinquenervia
- Family
- MyrtaceaeMyrtle family — also includes eucalyptus, clove, allspice
- Type
- Bee/insect-pollinated invasive tree (Florida Everglades invasive)
- Native to
- Australia and New Guinea; invasive in southern Florida (massive Everglades invasion in 20th century, now subject to major eradication program)
- Allergen proteins
- No IUIS-named Melaleuca pollen allergen as of May 2026Apparent sensitization in Florida SPT studies reflects bahiagrass cross-reactivity, not primary Melaleuca proteins (Stablein and Lockey, Ann Allergy Asthma Immunol 2002;89:523)
- Particle size
- Heavy, sticky — not aerosolized in clinical concentrations; bee-pollinated confirmation
- Avoidance difficulty
- Easy
How Melaleuca (Paperbark Tree) Allergy Presents
Symptoms by body system — useful for distinguishing Melaleuca (Paperbark Tree) sensitivity from overlapping allergies and infections.
Respiratory (actually bahiagrass — not melaleuca)
- Rhinitis and sneezing symptoms in Florida attributed to melaleuca are driven by windborne bahiagrass pollen per Stablein and Lockey 2002 — not by melaleuca pollen
- Melaleuca is bee-pollinated and its pollen is too heavy and sticky to become airborne in clinical concentrations
- Florida's extensive bahiagrass (Paspalum notatum) is a major warm-season grass aeroallergen with a long April–October season that overlaps entirely with melaleuca growing areas
Ocular (actually bahiagrass)
- Allergic conjunctivitis in southern Florida attributed to melaleuca almost always reflects bahiagrass or bermuda-grass sensitization
- Year-round ocular symptoms in Florida can also reflect perennial indoor allergens — dust mites (Dermatophagoides spp.) and cockroach — prevalent in Florida's humid climate
Dermal
- Tea tree oil (from the related Melaleuca alternifolia, not M. quinquenervia) is a documented cause of contact dermatitis in aromatherapy and skin-care product users
- Melaleuca quinquenervia sap can cause contact irritation in Everglades workers and eradication program staff
- No documented IgE pollen allergen from M. quinquenervia driving dermal sensitization
Systemic
- No published case reports of IgE-mediated systemic reactions attributable to Melaleuca quinquenervia pollen specifically
- Systemic allergy symptoms in southern Florida reflect the true primary sensitizers: bahiagrass, bermuda-grass, cockroach, dust mite, and ragweed
- Tea tree oil ingestion (M. alternifolia product) can cause systemic toxicity — a separate safety concern from pollen allergy
The Stablein 2002 paper is the most important southeastern aeroallergy publication you've never heard of — when a Florida patient skin-tests positive to melaleuca, the right next step is to test bahiagrass and treat that instead. The data proving cross-reactivity have been available for over two decades and should change clinical practice in the South.
When & Where Melaleuca (Paperbark Tree) Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Melaleuca bloom: year-round, peaks late summer–fall in Florida. Pollen is not airborne. Florida allergy symptoms year-round reflect bahiagrass (April–October), bermuda-grass, and perennial indoor allergens.· Bee-pollinated — no aeroallergen season. The Stablein 2002 cross-reactivity finding means melaleuca 'season' is not a meaningful clinical concept.
US Exposure Map
0 high-intensity statesWhat Melaleuca (Paperbark Tree) Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Melaleuca's clinical cross-reactivity story is documented: apparent Florida sensitization reflects bahiagrass windborne pollen cross-reacting with melaleuca extract, not primary Melaleuca sensitization per Stablein and Lockey 2002.
Is SCIT Right for Your Melaleuca (Paperbark Tree) Allergy?
If you live in Florida and have been told you are positive for melaleuca on an allergy test, these questions help clarify whether bahiagrass is the true primary sensitizer.
Do you live in or spend significant time in Florida?
The Melaleuca (Paperbark Tree) SCIT Protocol
SCIT for Melaleuca quinquenervia is not indicated based on the Stablein and Lockey 2002 evidence that apparent Florida melaleuca allergy reflects bahiagrass cross-reactivity. Treatment should target bahiagrass, which has FDA-standardized extracts available. Curex IgE testing screens specifically for bahiagrass and warm-season grass sensitization alongside melaleuca to confirm the true primary sensitizer before any treatment decision.
Florida patients with confirmed bahiagrass sensitization should receive bahiagrass SCIT build-up using FDA-standardized Paspalum notatum extract, following the standard 4–6 month weekly injection schedule with 30-minute observation period. Melaleuca extract should not be included in the mix.
Bahiagrass SCIT maintenance uses FDA-standardized extract. Including melaleuca in the maintenance mix is not evidence-based per the Stablein 2002 finding.
Not applicable. Bahiagrass SCIT discontinuation decisions follow the standard 3–5 year course recommendations.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Melaleuca (Paperbark Tree) SCIT
No SCIT efficacy data for melaleuca exist; the appropriate Florida allergy treatment target is bahiagrass, with FDA-standardized extract and robust clinical evidence from the warm-season grass SCIT literature.
- Florida SPT positivity to melaleuca extract (cross-reactive artifact)10%Stablein JJ, Lockey RF. Ann Allergy Asthma Immunol. 2002;89:523 — 97/1017 (9.5%) Florida patients SPT+, cross-reactivity with bahiagrass demonstrated
The Stablein and Lockey 2002 paper is the definitive clinical evidence for melaleuca allergy in Florida: the 9.5% SPT positivity observed in early Florida studies reflects cross-reactivity with windborne bahiagrass (Paspalum notatum), not primary sensitization to melaleuca pollen. Melaleuca is bee-pollinated with pollen too heavy to drive primary IgE sensitization; it has no IUIS-named allergen and no SCIT efficacy data. The correct clinical management for Florida patients testing positive to melaleuca is to confirm bahiagrass sensitization and target SCIT to bahiagrass, where FDA-standardized extract and established grass SCIT literature provide a robust evidence base.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Melaleuca (Paperbark Tree) SCIT Side Effects
SCIT for melaleuca is not indicated. Florida patients should receive bahiagrass SCIT, which follows the standard inhalant SCIT safety profile for FDA-standardized grass extracts.
Local reactions
2 documentedSystemic reactions
2 documentedAll bahiagrass SCIT visits require 30-minute at-home observation with epinephrine immediately available. Melaleuca SCIT is not indicated and adding it to a Florida grass mix would not be evidence-based practice.
SCIT vs Alternatives for Melaleuca (Paperbark Tree)
For Florida patients with apparent melaleuca allergy, the single most effective clinical intervention is switching the treatment target to bahiagrass — the proven actual sensitizer.
| Criterion | SCIT (bahiagrass — the true sensitizer)Best | SLIT Drops (bahiagrass) | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | Strong (FDA-standardized extract) | Moderate (extrapolated) | Moderate (grass avoidance difficult in FL) | Good symptom control |
| 5-yr cost | $3,500–$15,000 | $1,500–$4,000 | $0–$300/yr | $200–$1,200/yr |
| Duration | 3–5 years | 3–5 years | Indefinite | Indefinite |
| Convenience | Weekly then monthly clinic | Daily at home | Lifestyle adjustments | Daily April–October in FL |
| Safety | In-office 30-min wait | Self-administered | No medical risk | Generally safe |
| Lasting effect | 7–12 yrs post-course | Ongoing use needed | No lasting change | No lasting change |
SCIT (bahiagrass — the true sensitizer)Best
SLIT Drops (bahiagrass)
Avoidance
Medications
For Florida patients testing positive to melaleuca, redirecting the treatment target to bahiagrass is the most evidence-based next step. Curex IgE testing screens for bahiagrass and other warm-season grasses alongside melaleuca to identify the true primary sensitization per the Stablein 2002 evidence; once bahiagrass is confirmed, Curex delivers grass SCIT as a self-administered weekly shot at home for $129/month all-inclusive — a personalized serum sterile-compounded to USP <797>, with a prescribed epinephrine auto-injector confirmed on hand and your first dose plus every dose change supervised live over Zoom by the prescribing allergist — so you treat the actual Florida aeroallergen, not melaleuca.
What Melaleuca (Paperbark Tree) SCIT Actually Costs
Melaleuca SCIT lacks the evidence basis for insurance coverage. Bahiagrass SCIT using FDA-standardized Paspalum notatum extract is covered under standard allergy benefit codes when prescribed by a board-certified allergist with documented sensitization. Prior authorization typically required; insurer may require documentation of pharmacotherapy failure before approval.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
Flat monthly subscription — includes consult, prescription, and at-home dosing for sublingual immunotherapy.
See if you qualifyStop guessing about your melaleuca (paperbark tree) allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Melaleuca (Paperbark Tree) SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Stablein JJ and Lockey RF published in Ann Allergy Asthma Immunol 2002;89:523 the definitive study on melaleuca allergy in Florida. Prior data had shown that approximately 9.5% of Florida allergic patients (97 out of 1,017) tested positive on skin prick test to melaleuca extract, which superficially suggested melaleuca was a significant Florida aeroallergen. Stablein and Lockey's investigation revealed that these positive test results were explained by cross-reactivity with windborne bahiagrass (Paspalum notatum) pollen — not primary sensitization to melaleuca pollen. Melaleuca is bee-pollinated; its pollen does not enter the air in clinical concentrations. When patients' apparent melaleuca sensitization was explained by their pre-existing bahiagrass allergy, the epidemiologic case for melaleuca as a true aeroallergen collapsed. The implication is direct: SCIT for melaleuca is targeting the wrong allergen; bahiagrass is the appropriate target.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.